Global Interferon Market & Pipeline Analysis 2015

Jul 13, 2015, 14:59 ET from Research and Markets

DUBLIN, July 13, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/z2dllw/global_interferon) has announced the addition of the "Global Interferon Market & Pipeline Analysis 2015" report to their offering.
     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Interferon segment covers few diseases due to which they have modest market shares in pharmaceutical industry. Infectious diseases, few malignancies and Multiple Sclerosis are their major target group from which they generate revenues. Multiple sclerosis field is one of the highly developed segments which has numerous products and offer better performance than other therapeutics. In infectious diseases, they have significant effect and offers competition to vaccines which are one of the strongest pharmaceutical segments. In this segment, only for limited diseases they have very high pharmacological and commercialization potential due to which they are maintaining dominance in global market.

Hepatitis and AIDS-associated disease is one such segment which generates significant revenues. On the other hand, cancer segment shows similar trend but their role in combinatorial therapy can't be neglected due to which they have become important for treating cancer. Some of them are first-line cancer therapeutics and it is imperative to increase their number to offer sustained competition. In this way, interferons have become indispensible part of several disease segments but limited number of products seems to be the major limiting factor despite their superior pharmacological benefits.

During disease incidence, particular types of interferons or associated molecules are produced in body to provide protection against infectious agents. Interferon based diagnostics are relatively new concept for the market and they are expected to be used for several diseases. Mostly they would be used for identifying infectious disease because of their immunological origin. As a result, they would have higher resolution, precision, accuracy and reproducibility of results.

This technology is at nascent stages and it has to face severe competition from already existing diagnostics tests. Besides infectious disease, it could also be used for early cancer diagnosis due to which several lives could be saved. Diagnostically, they will have superior performance but their higher costs may cause some hinderance in their successful commercialization. With time, it is expected that the costs of developmental technology would decrease due to which more patients would be opting them to identify potential diseases.

Global Interferon Market & Pipeline Analysis 2015 Report Highlights:

  • Introduction & Classification of Interferons
  • Interferon Clinical Pipeline Country, Indication & Phase
  • Interferon Clinical Pipeline: 79 Drugs
  • Majority Interferon Drugs in Preclinical Phase: 29 Drugs
  • Marketed Interferon Drugs: 37 Drugs
  • Marketed Interferon Drug Clinical Insight & Patent Analysis
  • Global Interferon Market Future Prospects

Key Topics Covered:

1. Introduction to Interferon

2. Classification of Interferon

3. Mechanism of Interferon Therapeutics

4. Global Interferon Market Overview
4.1 Current Market Scenario
4.2 Interferon Pipeline Overview

5. Global Interferon Market Dynamics
5.1 Favorable Market Parameters
5.2 Commercialization Challenges

6. Global Interferon Market Future Prospects

7. Interferon Clinical Pipeline Country, Indication & Phase
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-III
7.9 Preregistration
7.10 Registered

8. Marketed Interferon Drug Insight by Company & Indication

9. Discontinued & Suspended & Interferon Drugs In Clinical Pipeline by Company Indication
9.1 No Development Reported
9.2 Discontinued
9.3 Suspended

10. Competitive Landscape
10.1 Amgen
10.2 BaroFold
10.3 Bayer
10.4 Boehringer Ingelheim
10.5 GalaxoSmithKline
10.6 Genetech
10.7 Helix BioPharma
10.8 Intas Biopharmaceuticals
10.9 Merck
10.10 Novartis
10.11 Pfizer
10.12 Roche
10.13 Swedish Orphan Biovitrum



For more information visit http://www.researchandmarkets.com/research/z2dllw/global_interferon


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets